▁Ch 10.375
iros 10.859375
cience 12.2578125
▁Group 7.41015625
▁pl 7.41015625
c 1.8173828125
, 5.47265625
▁a 5.0625
▁ren 8.578125
owned 0.93896484375
▁ph 6.86328125
arma 0.406494140625
ce 0.160400390625
ut 10.25
ical 0.1348876953125
▁research 5.796875
▁and 3.427734375
▁development 1.8681640625
▁company 2.634765625
▁based 3.7578125
▁in 0.2083740234375
▁Cambridge 4.8203125
, 0.403564453125
▁England 1.3115234375
, 0.63818359375
▁has 5.22265625
▁set 5.77734375
▁its 3.9375
▁s 1.8115234375
ights 0.01453399658203125
▁on 0.431396484375
▁a 2.501953125
▁potential 5.76171875
▁break 4.8515625
through 0.150634765625
▁in 2.09765625
▁ant 8.0078125
ican 2.994140625
cer 0.68408203125
▁treatment 2.998046875
. 2.099609375
▁The 2.126953125
▁company 2.181640625
▁has 1.66796875
▁successfully 4.80078125
▁identified 4.55859375
▁and 2.3203125
▁synth 4.06640625
es 0.0099334716796875
ized 0.1944580078125
▁two 3.875
▁novel 2.5625
▁comp 2.603515625
ounds 0.06884765625
▁that 1.5859375
▁exhib 3.830078125
it 0.0264892578125
▁prom 3.455078125
ising 0.007785797119140625
▁effic 4.40625
acy 0.0679931640625
▁against 1.888671875
▁various 3.80078125
▁types 1.3701171875
▁of 0.039398193359375
▁cancer 1.08203125
▁cells 1.77734375
▁in 2.96875
▁pre 2.966796875
cl 0.64697265625
in 0.0001442432403564453
ical 0.007205963134765625
▁studies 1.2890625
. 0.419189453125
▁With 5.14453125
▁further 4.8671875
▁assess 6.14453125
ment 0.58544921875
▁and 1.19140625
▁evaluation 3.294921875
▁in 2.896484375
▁human 2.23046875
▁tri 0.81005859375
als 0.0003933906555175781
, 0.30029296875
▁Ch 4.875
iros 1.591796875
cience 0.056396484375
▁hopes 3.091796875
▁to 0.11407470703125
▁contribute 5.49609375
▁significantly 2.56640625
▁to 0.3076171875
▁the 0.474853515625
▁fight 2.765625
▁against 0.043914794921875
▁cancer 0.368408203125
▁and 1.7216796875
▁provide 4.15625
▁hope 1.9345703125
▁to 0.671875
▁patients 1.46875
▁world 2.3828125
wide 0.019500732421875
. 0.26513671875
<0x0A> 0.482666015625
The 2.40234375
▁first 4.4296875
▁comp 1.55859375
ound 0.00971221923828125
, 1.1923828125
▁CS 6.92578125
- 0.9072265625
1 1.2138671875
2 2.65234375
4 2.6796875
, 1.0517578125
▁is 0.759765625
▁a 0.5234375
▁small 3.56640625
▁mole 0.205078125
c 0.010711669921875
ule 8.499622344970703e-05
▁that 1.5859375
▁has 1.7666015625
▁shown 1.6591796875
▁considerable 5.1328125
▁in 3.1640625
hib 0.72900390625
itory 0.253173828125
▁effects 2.015625
▁on 1.037109375
▁tum 3.734375
or 0.09075927734375
▁growth 0.98486328125
▁in 1.072265625
▁pre 1.3056640625
cl 0.03350830078125
in 2.276897430419922e-05
ical 0.0014410018920898438
▁models 2.78125
. 0.66259765625
▁Target 8.53125
ing 0.366455078125
▁specific 4.359375
▁signal 3.666015625
ing 0.1241455078125
▁path 0.09906005859375
ways 0.011077880859375
▁involved 2.62890625
▁in 0.026885986328125
▁the 1.46875
▁pro 1.453125
gression 0.88525390625
▁of 0.15380859375
▁cancer 0.60546875
, 0.72802734375
▁CS 0.84326171875
- 0.00405120849609375
1 0.00576019287109375
2 0.0031719207763671875
4 0.0009298324584960938
▁imp 9.0078125
edes 0.364990234375
▁the 0.98291015625
▁formation 3.9296875
▁and 1.8818359375
▁pro 1.2431640625
l 0.191162109375
ifer 0.00016129016876220703
ation 0.0016307830810546875
▁of 0.00396728515625
▁cancer 0.66064453125
▁cells 0.171875
. 1.0654296875
▁In 2.5703125
▁labor 5.16015625
atory 0.00611114501953125
▁experiments 2.4609375
, 0.1112060546875
▁it 2.701171875
▁has 0.7353515625
▁exhib 4.5859375
ited 0.00020945072174072266
▁particular 7.16796875
▁effect 3.431640625
iveness 0.11798095703125
▁against 0.463134765625
▁lung 3.365234375
▁and 1.984375
▁breast 1.2109375
▁cancer 0.316650390625
▁cells 0.426513671875
, 1.4892578125
▁both 3.634765625
▁of 0.62255859375
▁which 0.0026874542236328125
▁are 0.64111328125
▁pre 3.46875
val 0.02685546875
ent 0.01390838623046875
▁and 2.931640625
▁challeng 4.46484375
ing 0.0012569427490234375
▁to 0.9658203125
▁treat 0.2071533203125
▁effectively 6.671875
. 0.1361083984375
▁Under 6.76171875
lying 5.01953125
▁the 1.279296875
▁comp 3.5234375
ound 0.028656005859375
' 0.06304931640625
s 0.0007152557373046875
▁success 3.5078125
▁is 1.171875
▁its 0.58740234375
▁unique 2.390625
▁ability 2.046875
▁to 0.01276397705078125
▁bind 2.66796875
▁to 0.49072265625
▁a 1.80078125
▁critical 3.69921875
▁protein 1.6982421875
▁involved 2.798828125
▁in 0.0201416015625
▁cancer 1.7041015625
▁cell 0.407958984375
▁surv 3.294921875
ival 0.0011301040649414062
▁and 1.4189453125
▁promote 6.5
▁their 2.8046875
▁death 1.216796875
, 2.80859375
▁a 2.818359375
▁mechanism 2.658203125
▁that 0.90625
▁sets 6.59765625
▁it 0.9765625
▁apart 0.036590576171875
▁from 0.04241943359375
▁existing 3.27734375
▁treatment 3.65625
▁options 0.388916015625
. 0.276123046875
<0x0A> 0.5947265625
Build 7.90625
ing 0.0079345703125
▁upon 1.76171875
▁these 3.828125
▁prom 1.1611328125
ising 5.5670738220214844e-05
▁results 0.8896484375
, 0.08892822265625
▁Ch 0.38134765625
iros 0.0126800537109375
cience 0.00974273681640625
▁research 5.01953125
ers 0.043243408203125
▁have 1.0126953125
▁also 3.330078125
▁un 5.38671875
cover 0.11187744140625
ed 0.0002338886260986328
▁a 1.189453125
▁potential 3.494140625
▁imm 6.81640625
un 0.3251953125
other 0.496337890625
apy 0.6728515625
▁candidate 3.572265625
, 1.0283203125
▁CS 0.14794921875
- 0.006755828857421875
1 0.35888671875
7 3.841796875
2 2.48046875
, 0.72216796875
▁that 0.92919921875
▁could 3.767578125
▁revolution 5.39453125
ize 0.00783538818359375
▁the 1.021484375
▁landscape 6.9921875
▁of 0.055572509765625
▁cancer 0.24609375
▁treatment 0.30908203125
. 0.50048828125
▁Im 5.42578125
mun 0.2076416015625
other 0.01434326171875
apy 0.07403564453125
, 2.18359375
▁which 1.4169921875
▁har 3.66015625
ness 0.0005459785461425781
es 0.003238677978515625
▁the 0.051116943359375
▁body 0.95166015625
' 0.001155853271484375
s 0.0001462697982788086
▁imm 1.248046875
une 0.00812530517578125
▁system 0.1275634765625
▁to 0.1539306640625
▁target 2.830078125
▁and 0.79345703125
▁destroy 1.064453125
▁cancer 0.218994140625
▁cells 0.13916015625
, 0.0760498046875
▁has 0.49365234375
▁emer 4.125
ged 0.00029778480529785156
▁as 0.0212249755859375
▁a 0.498046875
▁ground 5.22265625
bre 0.174072265625
aking 0.0007252693176269531
▁approach 1.9931640625
▁in 1.787109375
▁recent 2.853515625
▁years 0.104736328125
. 0.685546875
▁CS 1.447265625
- 0.0013723373413085938
1 0.0009431838989257812
7 0.00562286376953125
2 0.0004661083221435547
, 1.2958984375
▁when 4.2265625
▁admin 1.3095703125
ister 0.00012314319610595703
ed 0.0001386404037475586
▁in 1.380859375
▁pre 4.1796875
cl 0.0128631591796875
in 7.033348083496094e-06
ical 0.0014829635620117188
▁studies 0.85791015625
, 0.1064453125
▁was 3.361328125
▁found 0.931640625
▁to 0.0173492431640625
▁stim 4.30078125
ulate 0.00019693374633789062
▁imm 3.228515625
une 0.1314697265625
▁cells 1.517578125
▁and 2.302734375
▁promote 1.8779296875
▁their 0.69677734375
▁ability 2.126953125
▁to 0.0018281936645507812
▁identify 3.4765625
▁and 0.329345703125
▁attack 2.220703125
▁cancer 0.267822265625
▁cells 0.150390625
, 2.009765625
▁effectively 2.873046875
▁bol 6.61328125
ster 0.0002868175506591797
ing 0.0008587837219238281
▁the 0.62744140625
▁imm 1.4814453125
une 0.0305023193359375
▁response 1.982421875
▁against 1.404296875
▁tum 1.35546875
ors 0.98779296875
. 0.2332763671875
▁This 3.162109375
▁comp 2.513671875
ound 0.00237274169921875
, 2.16796875
▁if 3.41015625
▁successful 2.763671875
, 0.9912109375
▁could 0.363525390625
▁provide 2.5390625
▁an 2.296875
▁alternative 2.109375
▁treatment 1.2568359375
▁strategy 3.787109375
▁for 0.69580078125
▁patients 1.044921875
▁who 2.08203125
▁have 0.92333984375
▁limited 4.78515625
▁options 1.421875
▁due 3.13671875
▁to 0.0030651092529296875
▁their 2.095703125
▁disease 3.3125
' 1.9833984375
s 0.0009174346923828125
▁nature 5.91796875
▁or 1.5341796875
▁pro 3.53125
gression 0.1641845703125
. 0.1597900390625
<0x0A> 0.1490478515625
Ex 6.2734375
c 1.904296875
iting 0.3369140625
▁as 2.189453125
▁these 0.48828125
▁pre 4.14453125
cl 0.283203125
in 2.288818359375e-05
ical 0.0018320083618164062
▁data 5.0078125
▁might 5.25390625
▁be 0.177978515625
, 0.0367431640625
▁the 1.3671875
▁ult 3.806640625
imate 0.0001379251480102539
▁validation 7.0
▁lies 4.14453125
▁in 0.25048828125
▁human 1.0810546875
▁tri 0.271484375
als 3.0994415283203125e-05
. 0.487060546875
▁Ch 1.494140625
iros 0.0090789794921875
cience 0.00855255126953125
▁Group 6.61328125
▁pl 2.15625
c 0.004787445068359375
▁is 1.3564453125
▁eager 3.951171875
▁to 0.133056640625
▁progress 4.86328125
▁the 1.634765625
▁comp 2.74609375
ounds 0.1441650390625
▁to 1.53515625
▁the 1.1201171875
▁next 0.96240234375
▁stage 1.080078125
, 2.046875
▁subject 6.33984375
ing 1.017578125
▁them 0.1300048828125
▁to 0.037567138671875
▁rig 1.7158203125
orous 0.005229949951171875
▁testing 1.4345703125
▁in 0.822265625
▁clin 2.587890625
ical 0.01181793212890625
▁tri 0.261962890625
als 2.682209014892578e-05
▁to 1.8291015625
▁assess 2.318359375
▁their 0.38818359375
▁safety 1.9091796875
▁and 0.296875
▁effic 0.2183837890625
acy 2.300739288330078e-05
▁in 1.765625
▁human 1.7060546875
▁volunte 5.76171875
ers 0.01009368896484375
. 0.1239013671875
▁The 1.80078125
▁company 1.03515625
▁plans 3.431640625
▁to 0.043304443359375
▁initi 2.994140625
ate 5.602836608886719e-05
▁these 2.470703125
▁tri 0.7890625
als 1.430511474609375e-06
▁within 2.806640625
▁the 0.1458740234375
▁next 0.272216796875
▁few 1.3515625
▁months 0.2059326171875
▁pending 7.83984375
▁regul 1.103515625
atory 0.0010280609130859375
▁appro 0.2880859375
val 5.888938903808594e-05
s 1.251953125
▁and 1.3974609375
▁sufficient 5.91015625
▁fund 0.33984375
ing 0.005512237548828125
, 2.87890625
▁with 2.099609375
▁hopes 3.734375
▁of 0.45703125
▁rec 5.56640625
ruit 0.0180816650390625
ing 0.01139068603515625
▁a 2.435546875
▁diverse 2.70703125
▁coh 3.197265625
ort 1.4662742614746094e-05
▁of 0.08087158203125
▁patients 1.1015625
▁representing 6.15625
▁different 2.2421875
▁cancer 1.94921875
▁types 0.1671142578125
. 1.0908203125
▁The 2.38671875
▁trial 4.30078125
▁design 2.421875
▁will 1.0517578125
▁follow 4.01171875
▁the 1.1435546875
▁highest 5.6171875
▁scientific 2.990234375
▁standards 0.736328125
▁and 1.1328125
▁ad 2.900390625
here 0.01190948486328125
▁to 0.047119140625
▁string 4.3515625
ent 0.0012063980102539062
▁eth 1.6845703125
ical 0.09466552734375
▁consider 4.81640625
ations 1.7881393432617188e-05
, 1.1044921875
▁ens 2.044921875
uring 0.00012040138244628906
▁patients 2.869140625
' 1.0654296875
▁w 3.576171875
elf 2.4557113647460938e-05
are 9.334087371826172e-05
▁and 0.66259765625
▁the 3.123046875
▁reli 5.66015625
ability 0.0013113021850585938
▁of 0.06951904296875
▁the 0.5751953125
▁obtained 8.6640625
▁data 0.4443359375
. 0.060302734375
<0x0A> 0.53125
" 2.73046875
We 1.2509765625
▁are 0.42138671875
▁genu 7.4296875
in 0.006999969482421875
ely 5.555152893066406e-05
▁excited 0.333984375
▁about 0.87109375
▁the 0.6962890625
▁potential 1.0986328125
▁of 0.564453125
▁these 0.8955078125
▁two 1.6708984375
▁comp 0.61865234375
ounds 0.0019893646240234375
," 1.916015625
▁said 0.6259765625
▁Dr 1.4306640625
. 0.048431396484375
▁Emma 7.53125
▁Johnson 5.83984375
, 0.1376953125
▁CE 2.173828125
O 0.00014519691467285156
▁of 0.298828125
▁Ch 0.09417724609375
iros 0.0118560791015625
cience 0.01334381103515625
▁Group 0.91015625
▁pl 0.1334228515625
c 0.0002048015594482422
, 2.982421875
▁during 5.5703125
▁a 0.73388671875
▁recent 0.63330078125
▁press 1.1875
▁conference 0.493896484375
. 0.16943359375
▁She 5.0859375
▁emphas 3.65234375
ized 0.0157928466796875
▁the 0.72705078125
▁ur 3.9140625
gent 0.72900390625
▁need 0.0662841796875
▁for 0.402099609375
▁novel 1.921875
▁th 2.833984375
era 1.71661376953125e-05
pe 6.556510925292969e-05
ut 1.6570091247558594e-05
ic 1.1806640625
▁options 1.1875
▁to 1.8994140625
▁combat 1.1259765625
▁the 2.373046875
▁dev 2.21484375
ast 0.0001169443130493164
ating 0.06268310546875
▁impact 1.3583984375
▁of 0.37548828125
▁cancer 0.0273284912109375
▁and 2.017578125
▁expressed 4.35546875
▁c 9.3125
aut 0.0386962890625
ious 0.01178741455078125
▁optim 0.037139892578125
ism 5.078315734863281e-05
▁about 1.03515625
▁the 0.37109375
▁out 4.61328125
comes 0.474853515625
, 6.08203125
▁based 5.03515625
▁upon 3.662109375
▁the 0.63916015625
▁rig 6.609375
orous 0.04150390625
▁pre 1.8291015625
cl 0.007205963134765625
in 2.372264862060547e-05
ical 0.003231048583984375
▁screen 6.73828125
ing 0.03143310546875
▁of 2.5390625
▁the 0.9423828125
▁comp 0.499755859375
ounds 0.0167694091796875
. 0.685546875
▁Dr 3.044921875
. 0.00567626953125
▁Johnson 0.058013916015625
▁also 1.8779296875
▁highlight 2.458984375
ed 0.0029010772705078125
▁the 0.256103515625
▁collabor 5.63671875
ative 0.042572021484375
▁efforts 1.5595703125
▁with 4.2734375
▁other 3.01171875
▁research 2.103515625
▁institutions 2.24609375
▁and 1.052734375
▁support 6.05859375
▁from 0.5634765625
▁various 3.71484375
▁fund 1.57421875
ing 0.134033203125
▁organizations 2.630859375
, 0.935546875
▁acknowled 5.58984375
ging 0.0134429931640625
▁the 0.382080078125
▁significance 3.6796875
▁of 0.0667724609375
▁a 4.21875
▁collect 4.28515625
ive 0.004886627197265625
▁commit 4.25390625
ment 0.0002123117446899414
▁to 0.3193359375
▁pushing 5.984375
▁forward 1.486328125
▁the 1.1943359375
▁boundaries 4.57421875
▁of 0.07415771484375
▁medical 3.197265625
▁science 0.99072265625
. 0.41357421875
<0x0A> 0.263916015625
Wh 4.45703125
ile 0.03857421875
▁the 1.1689453125
▁road 6.44140625
▁from 5.1875
▁pre 1.4326171875
cl 0.01038360595703125
in 7.987022399902344e-06
ical 0.00414276123046875
▁research 2.17578125
▁to 0.0677490234375
▁approved 5.84765625
▁ther 1.6162109375
ap 0.41455078125
ies 3.516674041748047e-05
▁is 0.8857421875
▁length 3.51171875
y 0.00399017333984375
▁and 0.66552734375
▁complex 1.8349609375
, 0.011962890625
▁Ch 0.56689453125
iros 0.005157470703125
cience 0.0035305023193359375
▁Group 0.7333984375
▁pl 0.09326171875
c 5.2094459533691406e-05
' 3.23046875
s 0.0016841888427734375
▁commit 2.583984375
ment 0.000972747802734375
▁to 0.124755859375
▁adv 3.439453125
ancing 0.050079345703125
▁these 2.806640625
▁potential 4.01171875
▁ant 5.95703125
ican 0.0018558502197265625
cer 0.0026378631591796875
▁comp 1.388671875
ounds 0.0005869865417480469
▁is 1.4853515625
▁a 3.298828125
▁g 7.1875
lim 0.53662109375
mer 0.0013761520385742188
▁of 0.0017518997192382812
▁hope 0.06353759765625
▁for 0.79150390625
▁cancer 1.85546875
▁patients 0.083740234375
▁and 2.001953125
▁their 0.62890625
▁families 0.5107421875
▁world 2.130859375
wide 0.0010690689086914062
. 0.051483154296875
▁Should 7.6484375
▁the 0.98388671875
▁human 5.2578125
▁tri 0.12493896484375
als 8.58306884765625e-06
▁prove 1.5107421875
▁successful 0.13916015625
, 0.11541748046875
▁these 2.8984375
▁comp 0.68994140625
ounds 0.0009675025939941406
▁have 2.615234375
▁the 0.204345703125
▁potential 0.03875732421875
▁to 0.015625
▁join 7.09375
▁the 0.475830078125
▁ranks 0.44287109375
▁of 0.00670623779296875
▁ground 5.1171875
bre 0.050384521484375
aking 6.92605972290039e-05
▁ther 2.67578125
ap 0.017059326171875
ies 1.9669532775878906e-05
▁and 2.26953125
▁transform 3.470703125
▁the 0.328125
▁landscape 0.28759765625
▁of 0.014312744140625
▁cancer 0.12164306640625
▁treatment 0.196533203125
. 0.52001953125
▁As 3.763671875
▁st 8.3359375
ake 0.52978515625
hold 0.030487060546875
ers 6.80685043334961e-05
▁eager 4.69921875
ly 0.3818359375
▁await 0.1171875
▁the 0.364501953125
▁init 5.82421875
iation 0.00021338462829589844
▁of 0.0308990478515625
▁clin 1.9892578125
ical 0.0005154609680175781
▁tri 0.06201171875
als 2.7418136596679688e-06
, 0.290771484375
▁the 1.673828125
▁potential 3.884765625
▁impact 1.72265625
▁of 0.380859375
▁Ch 2.626953125
iros 0.00516510009765625
cience 0.004131317138671875
' 0.55517578125
s 0.004543304443359375
▁dedic 6.97265625
ation 0.0002765655517578125
▁and 2.40234375
▁innov 2.7109375
ation 0.1788330078125
▁cannot 1.58203125
▁be 0.0185546875
▁under 1.326171875
st 0.288330078125
ated 0.00018739700317382812
. 0.07745361328125
